Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 12-Month Low – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $19.11 and last traded at $19.5410, with a volume of 18427 shares trading hands. The stock had previously closed at $20.18.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat, Ascentage Pharma Group International presently has an average rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Stock Down 3.9%

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $23.88 and a 200-day simple moving average of $26.74.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million during the quarter. On average, equities research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors have recently bought and sold shares of AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $96,000. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $204,000. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Finally, XY Capital Ltd lifted its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.